Phase 3Completed

A Study of Ezetimibe Added On to Rosuvastatin Versus Up Titration of Rosuvastatin in Patients With Hypercholesterolemia (MK0653-139)

A Multicenter, Randomized, Double-Blind, Titration Study to Evaluate the Efficacy and Safety of Ezetimibe Added On to Rosuvastatin Versus Up Titration of Rosuvastatin in Patients With Hypercholesterolemia at Risk for Coronary Heart Disease

Sponsor
Organon and Co (Industry)
Enrollment
440 enrolled
Conditions
Hypercholesterolemia
Interventions
Comparator: rosuvastatin 5 mg + ezetimibe 10 mg; Comparator: rosuvastatin 10 mg; Comparator: rosuvastatin 10 mg + ezetimibe 10 mg; Comparator: rosuvastatin 20 mg
Ages
adults, older adults
Registry
NCT00783263

Full record on ClinicalTrials.gov

From the registry

A study to evaluate the low-density lipoprotein cholesterol (LDL-C) lowering efficacy of the addition of ezetimibe to rosuvastatin compared with doubling dose of rosuvastatin in participants treated with rosuvastatin alone and not at their National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) LDL-C goal

Primary outcomes

  • Percent Change From Baseline in LDL-Cholesterol (mg/dL) After 6 Weeks of Treatment

History

  1. Last registry update

  2. Results first posted

  3. Primary completion

  4. Started

  5. Registered